Healio
SearchLoading
Healio
SearchLoading
21003793_EF156_THin_MM_collection_banner

Take Homes in Multiple Myeloma

Read more

June 24, 2021
5 min watch
Save

VIDEO: Selinexor combination highly active in heavily pretreated multiple myeloma

Once weekly selinexor, carfilzomib and dexamethasone was highly active and yielded deep responses in patients with heavily pretreated multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

“In patients that we treated at the recommended phase 2 dose, we achieved a response, which was kind of impressive, close to 80% and we had one-third of patients achieving a very good partial response,” Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.

Sources/Disclosures

Collapse
Source:

Gasparetto C, et al. Abstract 8038. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics

Read more from Take Homes in Multiple Myeloma

View all

Read more about

multiple myeloma
selinexor
duke university
heavily pretreated, high-risk multiple myeloma
 

Related Content